You are here: Industry Insights > Schizophrenia drug

News List

Sumitomo Dainippon publishes positive results of schizophrenia drug pharmaceutical-technology
July 23, 2019
Japanese pharma company Sumitomo Dainippon has announced its drug Lonasen (blonanserin) has achieved its primary endpoint in a Phase III trial of 150 adolescents with schizophrenia.
Teva plant tagged with warning letter for issues making schizophrenia drug fiercepharma
March 08, 2019
For years now, Teva has had difficulty with the laser drilling of a schizophrenia drug so that patients get the right dose. The FDA, having finally tired of the company being unable to resolve the issues, has now slapped the plant in Florida with a warnin
Lupin gets US FDA nod for generic schizophrenia drug expressbpd
January 08, 2019
The drug is a generic version os Sunovion Pharmaceuticals’ Latuda tablets
Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint fiercebiotech
December 26, 2018
Sunovion Pharmaceuticals and PsychoGenics unveiled positive phase 2 results for a new schizophrenia treatment that does not bind to the brain’s dopamine receptors.....
Lundbeck craters as resistant schizophrenia drug fails phase III pharmaphorum
December 19, 2018
Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.....
Alkermes preps filing for weight-friendly schizophrenia drug pharmaphorum
November 30, 2018
Alkermes is planning to head to the FDA next year with a new schizophrenia drug that, according to phase III data, could sidestep one of the main side effects of other drugs......